PROFUSA EXPANDS INTO MULTI-BILLION DOLLAR PRECISION DIAGNOSTICS MARKET WITH $30M LETTER OF INTENT FOR A PANOMICS PLATFORM
PROFUSA INC - UNDER LETTER OF INTENT, BIOINSIGHTS TO RECEIVE 3% ROYALTY ON NET REVENUE
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.